Iron status and iron supplementation in peritoneal dialysis patients

Kidney International, Supplement

Volumn 55, Issue 69, 1999, Pages

  Vychytil, Andreas ^a   Haag Weber, Marianne ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

Erythropoietin; Ferritin; Hypochromic red cells; Renal anemia; Transferrin

Indexed keywords

ERYTHROPOIETIN; FERRITIN; FERROUS GLUCONATE; IRON; IRON DEXTRAN; IRON SACCHARATE; TRANSFERRIN; RECOMBINANT ERYTHROPOIETIN;

CATHETER INFECTION; DOSE RESPONSE; DRUG FORMULATION; HEMATOCRIT; HUMAN; IMMUNE DEFICIENCY; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; IRON DEFICIENCY; IRON DEFICIENCY ANEMIA; IRON THERAPY; ORAL DRUG ADMINISTRATION; PERITONEAL DIALYSIS; PERITONITIS; PRIORITY JOURNAL; REVIEW; ANEMIA; BLOOD; CHRONIC KIDNEY FAILURE; IRON INTAKE; METABOLISM;

ADMINISTRATION, ORAL; ANEMIA; ERYTHROPOIETIN, RECOMBINANT; FERRITINS; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; IRON; IRON, DIETARY; KIDNEY FAILURE, CHRONIC; PERITONEAL DIALYSIS; TRANSFERRIN;

EID: 0032940723     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1999.055suppl.69071.x     Document Type: Review

References (91)

1. Anaemia of chronic renal failure. (editorial) Lancet 1:965-966, 1983
2. BLUMBERG AB, MARTI HRM, GRABER CG: Serum ferritin and bone marrow iron in patients undergoing continuous ambulatory peritoneal dialysis. JAMA 250:3317-3319, 1983
3. MCGONIGLE RJS, HUSSERL F, WALLIN JD, FISHER JW: Hemodialysis and continuous ambulatory peritoneal dialysis effects on erythropoiesis in renal failure. Kidney Int 25:430-436, 1984
4. CHARYTAN C, SPINOWITZ BS, GALLER M: A comparative study of continuous ambulatory peritoneal dialysis and center hemodialysis: Efficacy, complications, and outcome in the treatment of end-stage renal disease. Arch Intern Med 146:1138-1143, 1986
5. LINDBLAD AS, NOLPH KD: Hematocrit values in the CAPD/CCPD population: A report of the National CAPD Registry. Perit Dial Int 10:275-278, 1990
6. BESARAB A, GOLPER TA: Response of continuous peritoneal dialysis patients to subcutaneous recombinant human erythropoietin differs from that of hemodialysis patients. ASAIO Trans 37:M395-M396, 1991
7. GEERLINGS W, MORRIS RW, BRUNNER FP, BRYNGER H, EHRICH JHH, FASSBINDER W, RIZZONI G, SELWOOD NH, TUFVESON G, WING AJ: Factors influencing anaemia in dialysis patients. A special survey by the EDTA-ERA Registry. Nephrol Dial Transplant 8: 585-589, 1993
8. RAJA R, BLOOM E, GOLDSTEIN M, JOHNSON R: Erythropoietin with oral iron in peritoneal and hemodialysis patients: A comparison in an inner city population. ASAIO J 39:M578-M580, 1993
9. ZIMMERMAN SW, JOHNSON CA: Erythropoietin use in peritoneal dialysis patients. Am J Kidney Dis 18(Suppl 1):38-41, 1991
10. HOCKEN AG, MARWAH PK: Iatrogenic contribution to anaemia of chronic renal failure. Lancet 1:164-165, 1971
11. MILMAN N: Iron absorption measured by whole body counting and the relation to marrow iron stores in chronic uremia. Clin Nephrol 17:77-81, 1982
12. MILMAN N, CHRISTENSEN T, BARTELS U, LARSEN L: Iron absorption and iron status in patients with chronic uremia on regular peritoneal dialysis. Acta Med Scand 205:629-635, 1979
13. BERRY ER, RAMBACH WA, ALT HL, DEL GRECO F: Effect of peritoneal dialysis on erythrokinetics and ferrokinetics of azotemic anemia. Trans Am Soc Artif Int Organs 10:415-417, 1964
14. SALTISSI D, COLES GA, NAPIER J AF, BENTLEY P: The hematological response to continuous ambulatory peritoneal dialysis. Clin Nephrol 22:21-27, 1984
15. DE PAEPE MBJ, SCHELSTRAETE KHG, RINGOIR SMG, LAMEIRE NH: Influence of continuous ambulatory peritoneal dialysis on the anemia of endstage renal disease. Kidney Int 23:744-748, 1983
16. LAMPERI S, CAROZZI S, ICARDI A: In vitro and in vivo studies of erythropoiesis during continuous ambulatory peritoneal dialysis. Perit Dial Bull 3:94-96, 1983
17. MILMAN N, PEDERSEN NS, VISFELDT J: Serum ferritin in patients on regular peritoneal and haemodialysis treatment: Relation to marrow haemosiderin iron stores. Dan Med Bull 31:245-248, 1984
18. AKMAL M, SAWELSON S, KARUBIAN F, GADALLAH M: The prevalence and significance of occult blood loss in patients with predialysis advanced chronic renal failure (CRF), or receiving dialytic therapy. Clin Nephrol 42:198-202, 1994
19. ESCHBACH JW, EGRIE JC, DOWNING MR, BROWNE JK, ADAMSON JW: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: Results of a combined phase I and II clinical trial. N Engl J Med 316:73-78, 1987
20. VAN WYCK DB, STIVELMAN JC, RUIZ J, KIRLIN LF, KATZ MA, OGDEN DA: Iron status in patients receiving erythropoietin for dialysis-associated anemia. Kidney Int 35:712-716, 1989
21. MACDOUGALL IC, HUTTON RD, CAVILL I, COLES GA, WILLIAMS JD: Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously. BMJ 299:157-158, 1989
22. CHENG IKP, CY C, CHAN MK, YU L, FANG GX, WEI D: Correction of anemia in patients on continuous ambulatory peritoneal dialysis with subcutaneous recombinant erythropoietin twice a week: A long-term study. Clin Nephrol 35:207-212, 1991
23. STEVENS JM, AUER J, STRONG CA, HUGHES RT, OLIVER DO, WINEARLS CG, COTES PM: Stepwise correction of anaemia by subcutaneous administration of human recombinant erythropoietin in patients with chronic renal failure maintained by continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 6:487-494, 1991
24. BÁRÁNY P, CLYNE N, HYLANDER B, JOHANSSON AC, SIMONSEN O, LARSSON R, FRISENETIE-FICH C, SVENSSON B, HELMERS C: Subcutaneous epoetin beta in renal anemia: An open multicenter dose titration study of patients on continuous peritoneal dialysis. Perit Dial Int 15:54-60, 1995
25. NISSENSON AR, KORBET S, FABER M, BURKART J, GENTILE D, HAMBURGER R, MATTERN W, SCHREIBER M, SWARTZ R, VAN STONE J, WATSON A, ZIMMERMAN S: Multicenter trial of erythropoietin in patients on peritoneal dialysis. J Am Soc Nephrol 5:1517-1529, 1995
26. FALLER B, SLINGENEYER A, WALLER M, MICHEL C, GRÜTZMACHER P. MÜLLER HP, BARANY P, GRABENSEE B, ISSAD B, SCHMITT H, MEISL F: Daily subcutaneous administration of recombinant human erythropoietin (rhEPO) in peritoneal dialysis patients: A European dose-response study. Clin Nephrol 40:168-175, 1993
27. MILMAN N, CHRISTENSEN TE, PEDERSEN NS, VISFELDT J: Serum ferritin and bone marrow iron in non-dialysis, peritoneal dialysis and hemodialysis patients with chronic renal failure. Acta Med Scand 207:201-205, 1980
28. ALI M, RIGOLOSI R, FAYEMI AO, BRAUN EV, FRASCINO J, SINGER R: Failure of serum ferritin levels to predict bone-marrow iron content after intravenous iron-dextran therapy. Lancet 1:652-655, 1982
29. LIPSCHITZ DA, COOK JD, FINCH CA: A clinical evaluation of serum ferritin as an index of iron stores. N Engl J Med 290:1213-1216, 1974
30. BIRGEGÅRD G, HÄLLGREN R, KILLANDER A, VENGE P, WIDE L: Serum ferritin during infection. Acta Med Scand 205:641-645, 1979
31. LUI SF, LAW CB, TING SM, LI P, LAI KN: Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Clin Nephrol 36:246-251, 1991
32. MACDOUGALL IC, CAVILL I, HULME B, BAIN B, MCGREGOR E, MCKAY P, SANDERS E, COLES GA, WILLIAMS JD: Detection of functional iron deficiency during erythropoietin treatment: A new approach. BMJ 304:225-226, 1992
33. AKCICEK F, OZKAHYA M, CIRIT M, OK E, UNSAL A, TOZ H, CELIK A, ATABAY G, BASCI A: The efficiency of fractionated parenteral iron treatment in CAPD patients. Adv Perit Dial 13:109-112, 1997
34. KOOISTRA MP, VAN ES A, STRUYVENBERG A, MARX JJM: Iron metabolism in patients with the anaemia of end-stage renal disease during treatment with recombinant human erythropoietin. Br J Haematol 79:634-639, 1991
35. TARNG DC, CHEN TW, HUANG TP: Iron metabolism indices for early prediction of the response and resistance to erythropoietin therapy in maintenance hemodialysis patients. Am J Nephrol 15:230-237, 1995
36. JONNALAGADDA V, BLOOM EJ, RAJA RM: Importance of iron saturation for erythropoietin responsiveness in chronic peritoneal dialysis. Adv Perit Dial 13:113-115, 1997
37. CAVILL I: Diagnostic methods. Clin Haematol 11:259-273, 1982
38. SCHAEFER RM, SCHAEFER L: Management of iron substitution during r-HuEPO therapy in chronic renal failure patients: Erythropoiesis 3:71-75, 1992
39. KALANTAR-ZADEH K, HÖFFKEN B, WÜNSCH H, FINK H, KLEINER M, LUFT FC: Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era. Am J Kidney Dis 26:292-299, 1995
40. MACDOUGALL IC: How to get the best out of r-HuEPO. Nephrol Dial Transplant 10(Suppl 2):85-91, 1995
41. DRÜEKE TB, BÁRÁNY P, CAZZOLA M, ESCHBACH JW, GRÜTZMACHER P, KALTWASSER JP, MACDOUGALL IC, PIPPARD MJ, SHALDON S, VAN WYCK D: Management of iron deficiency in renal anemia: Guidelines for the optimal therapeutic approach in erythropoietin-treated patients. Clin Nephrol 48:1-8, 1997
42. FISHBANE S, MAESAKA JK: Current issues in iron management in end-stage renal disease. Semin Dial 10:5-8, 1997
43. FISHBANE S, FREI GL, MAESAKA J: Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 26:41-46, 1995
44. BONNAR J, GOLDBERG A, SMITH JA: Do pregnant women take their iron? Lancet 1:457-458, 1969
45. HALLBERG L, RYTTINGER L, SÖLVELL L: Side-effects of oral iron therapy: A double blind study of different iron compounds in tablet form. Acta Med Scand Suppl 459:1-10, 1966
46. MILMAN N, LARSEN L: Iron absorption in patients with chronic uremia undergoing regular hemodialysis. Acta Med Scand 199:113-119, 1976
47. ESCHBACH JW, COOK JD, SCRIBNER BH, FINCH CA: Iron balance in hemodialysis patients. Ann Intern Med 87:710-713, 1977
48. GOKAL R, MILLARD PR, WEATHERALL DJ, CALLENDER STE, LEDINGHAM JGG, OLIVER DO: Iron metabolism in haemodialysis patients. Q J Med 48:369-391, 1979
49. LAWSON DH, BODDY K, KING PC, LINTON AL, WILL G: Iron metabolism in patients with chronic renal failure on regular dialysis treatment. Clin Sci 41:345-351, 1971
50. DONNELLY SM, POSEN GA, ALI MAM: Oral iron absorption in hemodialysis patients treated with erythropoietin. Clin Invest Med 14:271-276, 1991
51. KOOISTRA MP, NIEMANTSVERDRIET EC, VAN ES A, MOL-BEERMANN NM, STRUYVENBERG A, MARX JJM: Iron absorption in erythropoietin-treated haemodialysis patients: Effects of iron availability, inflammation and aluminum. Nephrol Dial Transplant 13:82-88, 1998
52. MUIRHEAD N, BARGMAN J, BURGESS E, JINDAL KK, LEVIN A, NOLIN L, PARFREY P: Evidence-based recommendations for the clinical use of recombinant human erythropoietin. Am J Kidney Dis 26(Suppl 1): S1-S24, 1995
53. MILMAN N, CHRISTENSEN TE, BARTELS U, PEDERSEN NS: Iron status in patients undergoing regular peritoneal dialysis. Dan Med Bull 27:291-295, 1980
54. DOMOTO DT, MARTIN KJ: Failure of CAPD patients to respond to an oral iron absorption test. Adv Perit Dial 8:102-104, 1992
55. TINAWI M, MARTIN KJ, BASTANI B: Oral iron absorption test in patients on CAPD: Comparison of ferrous sulfate and a polysaccharide ferric complex. Nephron 74:291-294, 1996
56. FISHBANE S, MAESAKA JK: Iron management in end-stage renal disease. Am J Kidney Dis 29:319-333, 1997
57. JOHNSON CA, ROSOWSKI E, ZIMMERMAN SW: A prospective open-label study evaluating the efficacy and adverse reactions of the use of Niferex®-150 in ESRD patients receiving EPOGEN®. Adv Perit Dial 8:444-447, 1992
58. ANASTASSIADES EG, HOWARTH D, HOWARTH J, SHANKS D, WATERS HM, HYDE K, GEARY CG, LIU YIN JA, GOKAL R: Monitoring of iron requirements in renal patients on erythropoietin. Nephrol Dial Transplant 8:846-853, 1993
59. EISELE G, BAILIE GR, CLEMENT C, WONG E: Erythropoietin in continuous ambulatory peritoneal dialysis: Experience with subcutaneous administration. Perit Dial Int 12:34-36, 1992
60. STEINHAUER HB, LUBRICH-BIRKNER I, DREYLING KW, SCHOLLMEYER P: Effect of human recombinant erythropoietin on anaemia and dialysis efficiency in patients undergoing continuous ambulatory peritoneal dialysis. Eur J Clin Invest 21:47-52, 1991
61. NYVAD O, DANIELSEN H, MADSEN S: Intravenous iron-sucrose complex to reduce epoetin demand in dialysis patients. (letter) Lancet 344:1305-1306, 1994
62. MACDOUGALL IC, DAVIES ME, HUTTON RD, CAVILL I, LEWIS NP, COLES GA, WILLIAMS JD: The treatment of renal anaemia in CAPD patients with recombinant human erythropoietin. Nephrol Dial Transplant 5:950-955, 1990
63. SUH H, WADHWA NK: Iron dextran treatment in peritoneal dialysis patients on erythropoietin. Adv Perit Dial 8:464-466, 1992
64. VAN WYCK DB: Iron dextran in chronic renal failure. Semin Dial 4:112-114, 1991
65. HÖRL WH: How to get the best out of r-HuEPO. Nephrol Dial Transplant 10(Suppl 2):92-95, 1995
66. AMITAI I, ACKER M: Adverse effects of intramuscular iron injection. Acta Haematol 68:341-342, 1982
67. MACKINNON AE, BANCEWICZ J: Sarcoma after injection of intramuscular iron. BMJ 2:277-279, 1973
68. ALLEGRA V, MENGOZZI G, VASILE A: Iron deficiency in maintenance hemodialysis patients: Assessment of diagnosis criteria and of three different iron treatments. Nephron 57:175-182, 1991
69. HÖRL WH, CAVILL I, MACDOUGALL IC, SCHAEFER RM, SUNDER-PLASSMANN G: How to diagnose and correct iron deficiency during r-huEPO therapy: A consensus report. Nephrol Dial Transplant 11:246-250, 1996
70. SUNDER-PLASSMANN G, HÖRL WH: Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 10:2070-2076, 1995
71. AHSAN N, GROFF JA, WAYBILL MA: Efficacy of bolus intravenous iron dextran treatment in peritoneal dialysis patients receiving recombinant human erythropoietin. Adv Perit Dial 12:161-166, 1996
72. AHSAN N: Intravenous infusion of total dose iron is superior to oral iron in treatment of anemia in peritoneal dialysis patients: A single center comparative study. J Am Soc Nephrol 9:664-668, 1998
73. SILVERBERG DS, BLUM M, PEER G, KAPLAN E, IAINA A: Intravenous ferric saccharate as an iron supplement in dialysis patients. Nephron 72:413-417, 1996
74. SILVERBERG DS, IAINA A, PEER G, KAPLAN E, LEVI BA, FRANK N, STEINBRUCH S, BLUM M: Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis 27:234-238, 1996
75. CARTER TB, GARRIS AG, ULLIAN ME: Rusty peritoneal dialysis fluid after intravenous administration of iron dextran. Am J Kidney Dis 27:147-150, 1996
76. DIGENIS GE, RABINOVICH S, MEDLINE A, RODELLA H, WU G, OREOPOULOS DG: Electron microscopic study of the peritoneal kinetics of iron dextran during peritoneal dialysis in the rabbit. Nephron 37:108-112, 1984
77. PETER WLS, LAMBRECHT LJ, MACRES M: Randomized cross-over study of adverse reactions and cost implications of intravenous push compared with infusion of iron dextran in hemodialysis patients. Am J Kidney Dis 28:523-528, 1996
78. SUNDER-PLASSMANN G, HÖRL WH: Safety of intravenous injection of iron saccharate in haemodialysis patients. Nephrol Dial Transplant 11:1797-1802, 1996
79. THIRAYOTHIN P, CROSBY WH: The distribution of iron injected intraperitoneally: Evidence of serosal "absorption" by the small intestine. J Clin Invest 41:1206-1210, 1962
80. ROBINSON SC: Observations on the peritoneum as an absorbing surface. Am J Obstet Gynecol 83:446-452, 1962
81. MEHTA BC, PATEL JC: Total dose iron therapy using iron-dextran by intraperitoneal route. Indian J Med Sci 23:587-593, 1969
82. PARK SE, TWARDOWSKI ZJ, MOORE HL: Stability of iron concentrations in peritoneal dialysis solution bags. (letter) Perit Dial Int 17:210-211, 1997
83. SUZUKI K, TWARDOWSKI ZJ, NOLPH KD, KHANNA R, MOORE HL: Absorption of iron dextran from the peritoneal cavity of rats. Adv Perit Dial 11:57-59, 1995
84. PARK SE, TWARDOWSKI ZJ, MOORE HL, KHANNA R, NOLPH KD: Chronic administration of iron dextran into the peritoneal cavity of rats. Perit Dial Int 17:179-185, 1997
85. PECOITS-FILHO RFS, TWARDOWSKI ZJ, KIM YL, KHANNA R, MOORE H, NOLPH KD: The absence of toxicity in intraperitoneal iron dextran administration: A functional and histological analysis. Perit Dial Int 18:64-70, 1998
86. BASTANI B, GULLEY S: Intraperitoneal iron-dextran as a potential route of iron therapy in CAPD patients. (letter) Perit Dial Int 16:646-648, 1996
87. OKADA S, HAMAZAKI S, TOYOKUNI S, MIDORIKAWA O: Induction of mesothelioma by intraperitoneal injections of ferric saccharate in male Wistar rats. Br J Cancer 60:708-711, 1989
88. KOOISTRA MP, MARX JJM: The management of iron metabolism in recombinant human erythropoietin treated dialysis patients by Dutch nephrologists. Nephrol Dial Transplant 12:879-883, 1997
89. BLANCHARD R, BERGER W, BAILIE GR, EISELE G: Knowledge of hemodialysis and CAPD patients about their prescribed medicines. Clin Nephrol 34:173-178, 1990
90. SUNDER-PLASSMANN G, HÖRL WH: Erythropoietin and iron. Clin Nephrol 47:141-157, 1997
91. PATRUTA SI, EDLINGER R, SUNDER-PLASSMANN G, HÖRL WH: Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol 9:655-663, 1998